Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.74 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17423019 | 0.87 | SCN9A (0.82) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL15543308 | 0.86 | SCN9A (0.80) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL18570787 | 0.86 | SCN9A (0.70) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL19429993 | 0.85 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL18570784 | 0.81 | SCN9A (0.63) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL15599293 | 0.81 | SCN9A (0.71) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL28844267 | 0.79 | SCN9A (0.69) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL23677146 | 0.78 | SCN9A (0.67) | SCN9ASCN5ASCN1ASCN2ASCN7A | |
| SCHEMBL19411391 | 0.78 | SCN9A (0.73) | SCN9ASCN5ASCN7A | |
| SCHEMBL15543440 | 0.78 | SCN9A (0.68) | SCN9ASCN5ASCN1ASCN2ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2017035271-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | SCN9A 2486/4885SCN5A 1051/4885SCN1A 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.